REDESIGNING ANTIBODY DRUGS FROM THE GROUND UP
Xencor is expanding the therapeutic boundaries of monoclonal antibody drugs. Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases. 12 programs are in clinical testing, and many more are in preclinical development.